Figure 4. Pathway analysis of WGS and RNAseq results.

Whole genome and RNAseq data were integrated and analyzed using GeneGo's Metaminer Pancreatic Cancer Disease module to identify pathways that may be affected by mutations and/or significant expression changes (q-value<0.05, corrected). The top pathways (minimum mapping p-value across all WGS and RNAseq datasets <0.05) are summarized based off of GeneGo maps. Breakdown of affected pathways in each patient are shown in Table S4.